Polyrizon Ltd. announced that it has successfully produced a Good Manufacturing Practice (GMP) batch of clinical trial material (CTM) for its lead product candidate on March 10 2026. The new batch follows two prior development batches that confirmed batch‑to‑batch consistency and product stability, demonstrating the robustness of the company’s hydrogel platform.
The GMP‑compliant material will supply the planned U.S. clinical study later this year, removing a critical supply‑chain hurdle and enabling the company to submit regulatory dossiers and enroll trial participants without delay.
CEO Tomer Izraeli said the milestone “represents an important step in advancing our clinical development strategy” and highlighted that the successful GMP production “enables us to move forward with our planned U.S. clinical study.” The comment underscores how the event brings Polyrizon closer to regulatory approval and eventual commercialization of its intranasal barrier technology.
Polyrizon’s progress follows a December 2025 announcement of a manufacturing upscaling milestone for its PL‑14 Allergy Blocker and January 2025 preliminary work on GMP manufacturing. The company has a manufacturing agreement with Eurofins CDMO AmatsiAquitaine S.A.S., which supports the scale‑up and quality assurance of the product.
The completion of a GMP batch is a major operational milestone for a pre‑clinical biotech, marking a critical step toward human trials and potential market entry, and positioning Polyrizon to advance its intranasal delivery platform into the next phase of development.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.